Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372316 | 0.82 | MEN1 (0.64) | MEN1KMT2ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL23649319 | 0.81 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL5462238 | 0.79 | KCNH2 (0.73) | MEN1KMT2AFAAHPOLBALDH1A1 | |
| SCHEMBL314627 | 0.79 | FAAH (0.62) | MEN1KMT2AFAAHPOLB | |
| SCHEMBL4853191 | 0.79 | SLC6A2 (0.71) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL7362108 | 0.78 | FAAH (0.72) | MEN1KMT2AFAAHPOLBALDH1A1 | |
| SCHEMBL12685884 | 0.78 | MEN1 (0.71) | MEN1KMT2AFAAHPOLB | |
| SCHEMBL314501 | 0.78 | DRD2 (0.74) | MEN1KMT2APOLB | |
| SCHEMBL24075739 | 0.78 | SLC6A2 (0.70) | MEN1KMT2ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10548802 | 0.77 | DRD2 (0.48) | SLC6A4POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | claimed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | MEN1 2136/4885KMT2A 4074/4885SLC6A2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.